LENZ THERAPEUTICS INC Financials

LENZ

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows LENZ THERAPEUTICS INC (LENZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

LENZ THERAPEUTICS INC passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.19x

For every $1 of reported earnings, LENZ THERAPEUTICS INC generates $1.19 in operating cash flow (-$59.4M OCF vs -$49.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$58.6M

YoY+19.1%

LENZ THERAPEUTICS INC's EBITDA was -$58.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.1% from the prior year.

Free Cash Flow

-$59.9M

YoY+0.9%

LENZ THERAPEUTICS INC generated -$59.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 0.9% from the prior year.

Net Income

-$49.8M

YoY+28.9%

LENZ THERAPEUTICS INC reported -$49.8M in net income in fiscal year 2024. This represents an increase of 28.9% from the prior year.

EPS (Diluted)

$-2.34

LENZ THERAPEUTICS INC earned $-2.34 per diluted share (EPS) in fiscal year 2024. This represents an increase of 93.4% from the prior year.

Cash & Debt

$20.2M

YoY-42.6%

LENZ THERAPEUTICS INC held $20.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

28M

LENZ THERAPEUTICS INC had 28M shares outstanding in fiscal year 2024. This represents an increase of 1297.3% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$29.8M

YoY-49.9%

LENZ THERAPEUTICS INC invested $29.8M in research and development in fiscal year 2024. This represents a decrease of 49.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$468K

YoY+1460.0%

LENZ THERAPEUTICS INC invested $468K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1460.0% from the prior year.

LENZ Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$29.8M-49.9%	$59.5M-18.2%	$72.8M+91.9%	$37.9M+315.8%	$9.1M
SG&A Expenses	$28.8M+122.9%	$12.9M-60.7%	$32.9M+45.9%	$22.5M+414.3%	$4.4M
Operating Income	-$58.6M+19.1%	-$72.4M+31.4%	-$105.6M-74.8%	-$60.4M-347.7%	-$13.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A
Income Tax	$1K+100.6%	-$179K	$0	$0	$0
Net Income	-$49.8M+28.9%	-$70.0M+30.8%	-$101.1M-42.8%	-$70.8M-3.5%	-$68.4M
EPS (Diluted)	$-2.34	$-35.71	$-1.84+24.9%	$-2.45	N/A

Metric	Q3'25	Q2'25	Q3'24	Q2'24	Q4'23	Q3'23	Q4'22	Q3'22
Revenue	$12.5M+150.0%	$5.0M	$0	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.8M-58.2%	$9.1M+40.5%	$6.5M-7.1%	$6.9M	N/A	$17.0M	N/A	$18.3M
SG&A Expenses	$27.6M+115.7%	$12.8M+97.0%	$6.5M-12.3%	$7.4M	N/A	$2.9M	N/A	$7.9M
Operating Income	-$18.9M-12.0%	-$16.9M-30.2%	-$12.9M+9.8%	-$14.4M	N/A	-$19.9M	N/A	-$26.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0-100.0%	$500K	$0	$0	N/A	N/A	N/A	N/A
Net Income	-$16.7M-12.0%	-$14.9M-46.0%	-$10.2M+0.4%	-$10.3M	N/A	-$18.9M	N/A	-$24.7M
EPS (Diluted)	$-0.59-11.3%	$-0.53-39.5%	$-0.38+5.0%	$-0.40	N/A	$-9.62	N/A	$-0.45

LENZ Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$215.3M+205.9%	$70.4M-78.1%	$321.9M-19.9%	$402.0M+1681.5%	$22.6M
Current Assets	$211.9M+215.1%	$67.2M-75.6%	$275.4M-27.9%	$381.7M+1708.9%	$21.1M
Cash & Equivalents	$20.2M-42.6%	$35.1M-26.4%	$47.7M-87.3%	$377.0M+1805.7%	$19.8M
Inventory	$0	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.2M-93.1%	$163.1M-52.9%	$346.1M+1829.4%	$17.9M-79.6%	$88.0M
Current Liabilities	$10.4M-43.8%	$18.5M+41.9%	$13.0M+7.4%	$12.1M-62.1%	$32.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$204.1M+320.1%	-$92.7M-283.6%	-$24.2M-106.3%	$384.1M+687.2%	-$65.4M
Retained Earnings	-$145.0M-52.3%	-$95.2M+60.7%	-$242.4M-71.5%	-$141.4M-100.2%	-$70.6M

Metric	Q3'25	Q2'25	Q3'24	Q2'24	Q4'23	Q3'23	Q4'22	Q3'22
Total Assets	$210.7M-3.0%	$217.3M+0.9%	$215.3M+6.3%	$202.6M+187.9%	$70.4M-73.6%	$266.2M-17.3%	$321.9M-3.9%	$334.8M
Current Assets	$207.0M-3.1%	$213.6M+0.8%	$211.9M+6.3%	$199.3M+196.5%	$67.2M-71.8%	$238.8M-13.3%	$275.4M-7.7%	$298.5M
Cash & Equivalents	$25.4M-32.5%	$37.6M+86.6%	$20.2M-76.0%	$84.0M+139.1%	$35.1M-80.8%	$183.0M+283.4%	$47.7M-15.4%	$56.4M
Inventory	$949K	N/A	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.8M+53.0%	$11.0M-2.3%	$11.2M+15.5%	$9.7M-94.0%	$163.1M-51.4%	$335.8M-3.0%	$346.1M+1781.6%	$18.4M
Current Liabilities	$16.3M+56.9%	$10.4M-0.1%	$10.4M+21.2%	$8.6M-53.6%	$18.5M+47.7%	$12.5M-3.9%	$13.0M-3.6%	$13.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$193.9M-6.0%	$206.4M+1.1%	$204.1M+5.8%	$192.9M+308.1%	-$92.7M-33.3%	-$69.6M-187.8%	-$24.2M-107.6%	$316.5M
Retained Earnings	-$191.2M-9.6%	-$174.5M-20.4%	-$145.0M-18.7%	-$122.1M-28.2%	-$95.2M+72.3%	-$344.1M-42.0%	-$242.4M-11.3%	-$217.8M

LENZ Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$59.4M+1.6%	-$60.4M+31.4%	-$88.0M-66.5%	-$52.9M-506.0%	-$8.7M
Capital Expenditures	$468K+1460.0%	$30K-99.5%	$6.6M+14.9%	$5.7M+271.5%	$1.5M
Free Cash Flow	-$59.9M+0.9%	-$60.4M+36.1%	-$94.6M-61.4%	-$58.6M-470.7%	-$10.3M
Investing Cash Flow	-$154.5M-421.5%	-$29.6M+87.8%	-$241.9M-4113.6%	-$5.7M-271.5%	-$1.5M
Financing Cash Flow	$199.0M+146.6%	$80.7M+13417.6%	$597K-99.9%	$417.5M+1288.0%	$30.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q3'24	Q2'24	Q4'23	Q3'23	Q4'22	Q3'22
Operating Cash Flow	-$8.6M+25.4%	-$11.5M-26.8%	-$9.1M+42.5%	-$15.8M+24.7%	-$21.0M-60.2%	-$13.1M+41.6%	-$22.4M-1.0%	-$22.2M
Capital Expenditures	$439K+82.9%	$240K+61.1%	$149K+12.0%	$133K	$0	$0-100.0%	$1.0M+11.6%	$915K
Free Cash Flow	-$9.0M+23.2%	-$11.7M-27.3%	-$9.2M+42.1%	-$15.9M+24.0%	-$21.0M-60.2%	-$13.1M+44.2%	-$23.4M-1.4%	-$23.1M
Investing Cash Flow	-$4.3M-946.6%	-$414K+96.5%	-$11.9M+87.9%	-$98.4M-748.5%	$15.2M+184.7%	-$17.9M-232.5%	$13.5M+286.8%	$3.5M
Financing Cash Flow	$598K-97.7%	$26.5M+49877.4%	$53K+102.5%	-$2.1M-11.8%	-$1.9M-236.4%	-$568K-332.8%	$244K+513.6%	-$59K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LENZ Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A
Return on Assets	-23.1%+76.3pp	-99.4%-68.0pp	-31.4%-13.8pp	-17.6%+285.4pp	-303.0%
Current Ratio	20.36+16.7	3.63-17.5	21.11-10.3	31.44+30.8	0.66
Debt-to-Equity	0.06+1.8	-1.76+12.6	-14.32-14.4	0.05+1.4	-1.34
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q3'24	Q2'24	Q4'23	Q3'23	Q4'22	Q3'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-151.1%+186.0pp	-337.1%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-133.6%+164.6pp	-298.2%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-7.9%-1.1pp	-6.9%-2.3pp	-4.6%+0.5pp	-5.1%	N/A	-7.1%	N/A	-7.4%
Current Ratio	12.69-7.9	20.54+0.2	20.36-2.9	23.23+19.6	3.63-15.4	19.05-2.1	21.11-1.0	22.07
Debt-to-Equity	0.09+0.0	0.050.0	0.060.0	0.05+1.8	-1.76+3.1	-4.83+9.5	-14.32-14.4	0.06
FCF Margin	-72.2%+162.7pp	-235.0%	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Amylyx Pharmaceuticals AMLX

$1.6B

Tourmaline Bio TRML

$1.2B

Dianthus Therapeutics Inc DNTH

$2.1B

Trevi Therapeutics TRVI

$1.3B

Enliven Therapeutics Inc ELVN

$1.6B

Frequently Asked Questions

Is LENZ THERAPEUTICS INC profitable?

No, LENZ THERAPEUTICS INC (LENZ) reported a net income of -$49.8M in fiscal year 2024.

What is LENZ THERAPEUTICS INC's earnings per share (EPS)?

LENZ THERAPEUTICS INC (LENZ) reported diluted earnings per share of $-2.34 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is LENZ THERAPEUTICS INC's EBITDA?

LENZ THERAPEUTICS INC (LENZ) had EBITDA of -$58.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is LENZ THERAPEUTICS INC's free cash flow?

LENZ THERAPEUTICS INC (LENZ) generated -$59.9M in free cash flow during fiscal year 2024. This represents a 0.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is LENZ THERAPEUTICS INC's operating cash flow?

LENZ THERAPEUTICS INC (LENZ) generated -$59.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are LENZ THERAPEUTICS INC's total assets?

LENZ THERAPEUTICS INC (LENZ) had $215.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are LENZ THERAPEUTICS INC's capital expenditures?

LENZ THERAPEUTICS INC (LENZ) invested $468K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does LENZ THERAPEUTICS INC spend on research and development?

LENZ THERAPEUTICS INC (LENZ) invested $29.8M in research and development during fiscal year 2024.

How many shares does LENZ THERAPEUTICS INC have outstanding?

LENZ THERAPEUTICS INC (LENZ) had 28M shares outstanding as of fiscal year 2024.

What is LENZ THERAPEUTICS INC's current ratio?

LENZ THERAPEUTICS INC (LENZ) had a current ratio of 20.36 as of fiscal year 2024, which is generally considered healthy.

What is LENZ THERAPEUTICS INC's debt-to-equity ratio?

LENZ THERAPEUTICS INC (LENZ) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is LENZ THERAPEUTICS INC's return on assets (ROA)?

LENZ THERAPEUTICS INC (LENZ) had a return on assets of -23.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is LENZ THERAPEUTICS INC's cash runway?

Based on fiscal year 2024 data, LENZ THERAPEUTICS INC (LENZ) had $20.2M in cash against an annual operating cash burn of $59.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is LENZ THERAPEUTICS INC's Piotroski F-Score?

LENZ THERAPEUTICS INC (LENZ) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LENZ THERAPEUTICS INC's earnings high quality?

LENZ THERAPEUTICS INC (LENZ) has an earnings quality ratio of 1.19x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.